While this could potentially be a source of bias, we included only those patients who fulfilled clinical diagnostic criteria in combination with other objective markers, i.e., CSF biomarkers in AD and dopamine transporter imaging in DLB. This evidence concerns the gene SLC6A3 and Lewy body dementia.